Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial[J]. N Engl J Med, 2005, 352(11): 1092-1102.
[2]
Solomon SD, McMurray JV, Pfefer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention [J]. N Engl J Med, 2005, 352(11): 1071-1080.
Buerkle MA, Lehrer S, Sohn HY, et al. Selective Inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo [J]. Circulation, 2004, 110 (14): 2053-2059.
[7]
Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J]. Arch Intern Med, 2005, 165 (5): 490-496.
[8]
Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus [J]. Arch Intern Med, 2005, 165 (2): 161-168.
[9]
Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo[J ]. J Clin Invest, 2001, 108(4): 585-590.
[10]
Delgado RM, Nawar MA, Zewail AM, et al. Cyclooxygenase-2 inhibit or treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure [J]. Circulation, 2004, 109 (11): 1428-1433.
[11]
LaPointe MC, Mendez M, Leung A, et al. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse[J]. Am J Physiol Heart Circ Physiol, 2004, 286 (4): 1416-1424.
[12]
Saito T, Rodger IW, Hu F, et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction[J]. Biochem Biophys Res Commun, 2000, 273(2): 772-775.
[13]
Brinker A, Goldkind L, Bonnel R, et al. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib,celecoxib, nabumetone and oxaprozin[J]. Drugs Aging, 2004, 21(7): 479-484.
[14]
Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics[J]. Hypertension, 2004, 43(3): 573-577.
[15]
Blais V, Turrin NP, Rivest S. Cyclooxygenase 2 (COX？2) inhibition increases the inflammatory response in the brain during systemic immune stimuli[J]. J Neurochem, 2005, 95(6): 1563-1574.
[16]
Zhang F, Warskulat U, Wettste M, et al. Hyperosmolarity stimulates prostaglandin synthesis and cyclooxygenase-2 expression in activated rat liver macrophages[J]. Biochem J, 1995, 312(Pt1): 135-143.
[17]
Smith WL, De Witt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs[J]. Semin Nephrol, 1995, 15(3): 179-194.
[18]
Song YG, Kwon HM, Kim JM, et al. Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae[J]. Yonsei Med J, 2000, 41(3): 319-327.
[19]
Song W, Furman BL, Parratt JR. Delayed protection against ischemia-induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin[J]. Br J Pharmacol, 1996, 118 (8): 2157-2163.
[20]
Feng L, Xia Y, Garcia GE, et al. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha and lipopolysaccharide[J]. Clin Invest, 1995, 95(4): 1669-1675.
[21]
Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin [J]. Circulation, 1999, 100(8): 793-798.
[22]
Chenevard R, Hürlimann D, Béchir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease[J]. Circulation, 2003, 107(3): 405-409.
[23]
Wang K, Tarakji KM, Zhou Z, et al. Celecoxib a selective cyclooxygenase-2 inhibitor, decreased monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model[J]. J Cardiovas Pharm, 2005, 45(1): 61-67.
Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression related to prostaglandin biosynthesis and angiogenesis in human gastric cancer [J]. Clin Cancer Res, 2000, 6(1): 135-138.
Gopez JJ, Yue HF, Vasudevan R, et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes provides neuroprotection and reduces inflammation in a rat model of traumatic brain injury[J]. Neurosurgery, 2005, 56(3): 590-604.
[29]
Iadecola C, Gorelick PB. The janus face of cycloxygenase-2 in ischemic stroke: shifting toward downstream targets[J]. Stroke, 2005, 36(2): 182-185.
[30]
Mosheimer BA, Kaneider NC, Feistritzer C. CD4 0ligand-dependent induction of cox-2 gene expression in endothelial cells by activated platelets inhibitory effects of atorvastatin[J]. Blood Coagu Fibri, 2005, 16(2): 105-110.
[31]
Whelton A, John G, Joseph A, et al. cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients[J]. Am J Ther, 2001, 8(2): 85-95.
